Introduction {#s1}
============

Hematopoiesis in humans begins with stem cell migration from fetal liver through the periphery to the stromal area of hematopoietic tissue where cells are retained, differentiated, and released as maturing progenitor cells back into the periphery. Progenitor cells subsequently migrate to functionally unique tissues such as thymus for further steps of locally-defined differentiation. Pools of stem cells and progenitor cells are retained in hematopoietic tissue throughout life providing a microenvironment for progenitor cell renewal [@pone.0031383-Yahata1]. In human adults, hematopoiesis is dependent on the chemokine receptor CXCR4 and its ligand CXCL12 with an additional role played by cell surface human leukocyte elastase (HLE~CS~), and these components are motogenic [@pone.0031383-Lapidot1]--[@pone.0031383-Cepinskas1].

Mutations in the HLE-encoding gene *ELA2* produce periodic cycling in hematopoiesis that affect monocytes and neutrophils [@pone.0031383-Horwitz1], [@pone.0031383-Horwitz2]. HLE~CS~ and its granule-released counterpart (HLE~G~) are synthesized as a single molecular protein that is trafficked to the cell surface early in ontogeny and is then redirected by C-terminal processing to the granule compartment later in ontogeny [@pone.0031383-Benson1]--[@pone.0031383-Garwicz1]. Generally, HLE mutations that prevent its localization to the plasma membrane cause cyclic neutropenia, while mutations that cause exclusive localization to the plasma membrane cause severe congenital neutropenia [@pone.0031383-Benson1]. Individuals carrying a mutation in the transcriptional repressor oncogene *GFI1* which targets *ELA2*, synthesize twice more HLE, twice fewer absolute numbers of circulating CD4^+^ and CD8^+^ lymphocytes, and 7 times more monocytic cells [@pone.0031383-Person1]. Thus, as opposed to the well characterized enzymatic function of HLE~G~, the primary functions of HLE~CS~ appear to be cell migration and hematopoiesis [@pone.0031383-Lapidot1], [@pone.0031383-Cepinskas1], [@pone.0031383-Banda1].

The physiologic ligand for HLE~CS~ is α~1~proteinase inhibitor (α~1~PI, α~1~antitrypsin, *SerpinA1*) which is synthesized in hematopoietic and hepatic tissue [@pone.0031383-Kuiperij1]. Evidence suggests that α~1~PI also participates in hematopoiesis, specifically thymopoiesis [@pone.0031383-Bristow1]. During thymopoiesis, a cluster of mouse genes are expressed sequentially and were previously identified to encode the T cell alloantigens, Tpre, Tthy, Tind, and Tsu [@pone.0031383-Owen1]. The chromosomal location of these maturational markers corresponds to that of α~1~PI, and using monoclonal antibodies that discriminate these mouse maturational markers, the human equivalent was identified as α~1~PI [@pone.0031383-Bristow2].

The motogenic activities of HLE~CS~ and α~1~PI involve direct or indirect interaction with Mac-1, an α~M~β~2~ integrin [@pone.0031383-Cai1], and members of the LDL receptor family [@pone.0031383-Strickland1], [@pone.0031383-Cao1]. In addition, α~1~PI-HLE~CS~ complexes co-localize with the receptors CD4 and CXCR4 in polarized cells, an activity that promotes cell migration and facilitates HIV-1 binding and infectivity [@pone.0031383-Banda1], [@pone.0031383-Bristow3], [@pone.0031383-Bristow4]. We and others have shown that pretreatment of cells with α~1~PI and other ligands of HLE~CS~ for 60 min inhibits HIV-1 binding and infectivity [@pone.0031383-Bristow5]--[@pone.0031383-Munch1]. In contrast, we have also shown that pretreatment of cells with α~1~PI for 15 min facilitates HIV-1 binding and infectivity [@pone.0031383-Bristow3]. These opposing effects of α~1~PI may be due to the kinetics of α~1~PI--induced cell migration which begins with receptor polarization at the leading edge of the migrating cell and concludes with endocytosis of the receptor aggregate at the trailing edge of the cell [@pone.0031383-Cao1]. After 60 min incubation with α~1~PI, the HIV-1 receptor aggregate has been internalized rendering cells temporally unable to bind to HIV-1 [@pone.0031383-Shapiro1], [@pone.0031383-Munch1]. Thus, it is likely that the principal influence of α~1~PI on HIV-1 binding and infectivity is due to its extracellular activities.

Alternative mechanisms of action have been suggested for the α~1~PI effect on HIV-1 infectivity including that it is both an inhibitor of and is a substrate of two proteinases, the HIV-1 aspartyl protease and the host proteinase furin, both of which participate in processing viral proteins [@pone.0031383-Cordelier1]. Like other serine proteinase inhibitors, α~1~PI forms an irreversible, covalent-like complex with its cognate proteinase, HLE~G~ or HLE~CS~, thereby inhibiting elastolytic activity. The binding of α~1~PI to the catalytic site within HLE interrupts the electron transfer mechanism of the catalytic triad. Cleavage is not completed, and α~1~PI is not cleaved [@pone.0031383-Martodam1]. Interaction of α~1~PI with serine proteinases other than HLE, for example furin, can produce cleavage, and in this case, α~1~PI is acting as a substrate, not an inhibitor [@pone.0031383-Misumi1]. The evidence that α~1~PI is a substrate for the HIV-1 aspartyl protease implies α~1~PI competes with the protease\'s natural substrate (Gag-Pol) such that the decreased cleavage of Gag-Pol detected was due to substrate competition, rather than inhibition.

In addition to hepatocytes, α~1~PI is produced in bone marrow, by lymphocytic and monocytic cells in lymphoid tissue, and by the Paneth cells of the gut [@pone.0031383-Winkler1], [@pone.0031383-Molmenti1]. Since α~1~PI therapy in our previous study produced increased CD4 numbers in PIzz as it did in HIV-1 patients, it can be interpreted that α~1~PI in circulation contributes to CD4 numbers [@pone.0031383-Bristow1]. Since PIzz patients have very low blood concentrations of α~1~PI and do not consistently exhibit below normal CD4 numbers, it can be interpreted that α~1~PI produced in bone marrow and lymphocytic tissue also contribute to regulating CD4 numbers.

The kinetics of T cell death and proliferation has explained, in part, the short-term depletion of the circulating pool of CD4^+^ T cells in HIV-1 infection [@pone.0031383-Ribeiro1]; however, an explanation for their long-term depletion is absent and involves both depletion of the circulating pool and depression of hematopoiesis [@pone.0031383-Bristow1], [@pone.0031383-Hellerstein1]. It was previously demonstrated that in HIV-1 disease, α~1~PI is severely deficient suggesting that insufficient α~1~PI could impede thymopoiesis [@pone.0031383-Bristow6]. In a longitudinal study, the number of immunocompetent CD4^+^ lymphocytes in HIV-1 subjects was found to increase to normal levels within 2 weeks of initiating α~1~PI augmentation therapy, and this suggests that α~1~PI participates in regulating the number of circulating CD4^+^ lymphocytes [@pone.0031383-Bristow1]. Herein is shown that in a cross-sectional study, α~1~PI correlates with the number of CD4^+^ lymphocytes in HIV-1 subjects. The presence of anti-HIV-1 IgG-α~1~PI immune complexes in HIV-1 patients is shown to cause the attendant functional deficiency in α~1~PI.

Results {#s2}
=======

Lymphocyte numbers are regulated by α~1~PI {#s2a}
------------------------------------------

In healthy individuals, the concentration of α~1~PI in serum ranges from 18--53 µM between the 5^th^ and 95^th^ percentiles, and 90--100% of this protein is in its active form as determined by inhibition of porcine pancreatic elastase [@pone.0031383-Bristow6]. To investigate the relationship between active serum α~1~PI concentration, HLE~CS~ ^+^, and CD4^+^ lymphocyte numbers, blood was collected from 30 healthy HIV-1 uninfected adults, 14 males and 16 females ([**Table 1**](#pone-0031383-t001){ref-type="table"}). Neither serum active α~1~PI, serum CXCL12, HLE~CS~ ^+^ lymphocytes, or CXCR4^+^ lymphocytes, were independently correlated with CD4^+^ lymphocytes. However, using multilinear regression analysis it was found that higher CD4^+^ lymphocytes were significantly correlated with a combination of factors including higher serum active α~1~PI, lower HLE~CS~ ^+^ lymphocyte numbers, and higher CXCR4^+^ lymphocyte numbers (r^2^ = 0.91, p\<0.001). Neither serum CXCL12 (r^2^ = 0.21) nor CCR5^+^ lymphocytes (r^2^ = 0.56) were significantly correlated with CD4^+^ lymphocytes. Using multilinear regression, absolute lymphocyte numbers (T B, and NK cells) were correlated with CXCR4^+^ lymphocytes (r^2^ = 0.90, p\<0.001), but not with HLE~CS~ ^+^ lymphocytes, serum active α~1~PI or serum CXCL12. These results are consistent with a regulatory pathway for CD4^+^ lymphocyte numbers that includes active α~1~PIand the receptors CXCR4 and HLE~CS~.

10.1371/journal.pone.0031383.t001

###### Regression analysis of CD4^+^ and absolute lymphocyte numbers in HIV-1 uninfected subjects.

![](pone.0031383.t001){#pone-0031383-t001-1}

                                            Independent Variables                                     
  ---------------------------------------- ----------------------- ---------- ----------- ----------- -------------------------------
  **CD4^+^ Ly**1024±415 cells/µl, n = 32          p\<0.001          p\<0.001   p\<0.001    p = 0.965   r^2^ = 0.92, p\<0.001, n = 31
  **Total Ly**2265±746 cells/µl, n = 35           p = 0.540         p\<0.001   p = 0.812   p = 0.264   r^2^ = 0.91, p\<0.001, n = 31

Values for independent and dependent variables represent mean ± standard deviation. HLE~CS~ ^+^ lymphocytes and CXCR4^+^ lymphocytes in the lymphocyte gate (Ly) were quantitated using flow cytometry. Active α~1~PI and CXCL12 were quantitated in serum as described.

Multilinear regression was performed to determine the relationship of the dependent variables to the independent variables using power of test α = 0.05. Dependent variables were considered to be significantly related to the independent variable if they contributed significantly to the multilinear regression (p\<0.05). In this population sample, variables were found to have constant variance and normality.

α~1~PI is correlated with CD4^+^ lymphocyte numbers in HIV-1 disease {#s2b}
--------------------------------------------------------------------

In the cross-sectional study population, blood was collected from 35 HIV-1 infected adults, 33 males and 2 females. Of these 35, 26 were found to have \>220 CD4 cells/µl and 9 to have \<220 CD4 cells/µl at the time of blood collection. All HIV-1 infected subjects were measured for numbers of CD4^+^, CXCR4^+^, and CCR5^+^ lymphocytes, as well as serum concentrations of CXCL12 as well as total, active, and inactive α~1~PI. Of these 35 subjects, 11 had active liver disease as defined by detectable Hepatitis B or C, or elevated liver enzymes. HIV-1 infected subjects with liver disease were not different from HIV-1 infected subjects without liver disease in serum active α~1~PI (p = 0.95), serum total α~1~PI (p = 0.79), CXCR4^+^ lymphocytes (p = 0.63), or CCR5^+^ lymphocytes (p = 0.9), but exhibited significantly higher serum CXCL12 (p\<0.001), HLE~CS~ ^+^ lymphocytes (p\<0.001), and CD4^+^ lymphocytes (p = 0.04).

In the 26 HIV-1 infected subjects with \>220 CD4 cells/µl, absolute lymphocyte counts were significantly lower in HIV-1 infected subjects than HIV-1 uninfected subjects (p = 0.03) as were CXCR4^+^ lymphocytes (p = 0.001), CD4^+^ lymphocytes (p\<0.001), and active α~1~PI (p\<0.001). On the other hand, total α~1~PI (p = 0.003) and inactive α~1~PI (p\<0.001) were significantly higher in HIV-1 infected subjects. In these HIV-1 infected subjects, higher CD4^+^ lymphocyte numbers were correlated with higher concentration of serum active α~1~PI (r^2^ = 0.927, p\<0.0001) and lower concentration of serum inactive α~1~PI (r^2^ = 0.946, p\<0.0001) ([**Fig. 1A**](#pone-0031383-g001){ref-type="fig"}).

![Correlation between α~1~PI, IgG-α~1~PI immune complexes, and CD4^+^ lymphocytes in HIV-1 infected subjects.\
(**A**) In subjects with \>220 CD4 cells/µl, CD4^+^ lymphocyte levels correlate with active α~1~PI (r^2^ = 0.927, p\<0.0001, n = 26). CD4^+^ lymphocyte levels also correlate with inactive α~1~PI, (r^2^ = 0.906, p\<0.0001, n = 26). Subjects receiving protease inhibitor therapy are depicted by red squares. All other subjects are depicted by black circles. In the 9 subjects with \<220 CD4 cells/µl, no correlation was found to exist between CD4^+^ lymphocyte levels and active α~1~PI. Non-linear regression was performed using a 3 parameter Sigmoid curve with power of test α = 0.05. In this population, all variables were found to have normality and constant variation. (**B**) In 8 of 35 subjects, IgG-α~1~PI immune complexes were detected and were correlated with CD4^+^ lymphocyte levels (r^2^ = 0.822, p = 0.05) and with inactive α~1~PI (r^2^ = 0.988, p\<0.0001).](pone.0031383.g001){#pone-0031383-g001}

Regression analysis revealed a sigmoidal relationship between CD4^+^ lymphocyte numbers and active α~1~PI or inactive α~1~PI, and this is typical of many biological relationships in which a linear relationship reaches plateau at saturation ([**Fig. 1A**](#pone-0031383-g001){ref-type="fig"}). In contrast, in HIV-1 uninfected subjects, there was no apparent sigmoidal relationship between CD4^+^ lymphocyte numbers and active α~1~PI (r^2^ = 0.20) or inactive α~1~PI (r^2^ = 0.22), and this is due to the multiple interacting relationships between CD4^+^ lymphocytes and CXCR4^+^ lymphocytes, CXCL12 and active α~1~PI.

Of these 26 subjects, 21 were additionally measured for HLE~CS~. As in the HIV-1 uninfected population, HLE~CS~ ^+^ lymphocyte numbers were not independently correlated with CD4^+^ lymphocyte numbers, but in combination with higher serum active α~1~PI concentration, lower HLE~CS~ ^+^ lymphocytes were significantly correlated with CD4^+^ lymphocyte numbers (p = 0.01) ([**Table 2**](#pone-0031383-t002){ref-type="table"}). In subjects with \<220 CD4 cells/µl, there was no relationship between CD4^+^ lymphocyte numbers and active or inactive α~1~PI concentrations in serum ([**Fig. 1A**](#pone-0031383-g001){ref-type="fig"}), and this suggests either HIV-1 itself, or other host processes contribute to disrupting the regulation of CD4^+^ lymphocyte numbers, a question presently being addressed in a separate manuscript (unpublished observations). CD4^+^ lymphocyte numbers were not found to correlate with CXCR4^+^ lymphocyte numbers or CCR5^+^ lymphocyte numbers individually or in combination with any parameters of disease being investigated in these HIV-1 infected subjects, and this suggests that although these chemokine receptors participate during HIV-1 entry, they do not participate in the pathologic decrease in CD4^+^ lymphocytes.

10.1371/journal.pone.0031383.t002

###### Regression analysis of CD4^+^ and absolute lymphocyte numbers in HIV-1 infected subjects.
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                                           Independent Variables[a](#nt103){ref-type="table-fn"}                                     
  --------------------------------------- ------------------------------------------------------- ----------- ---------- ----------- --------------------------------
  **CD4^+^ Ly**503±210 cells/µl, n = 26                          p = 0.011                         p = 0.695   p\<0.001   p = 0.766   r^2^ = 0.64, p = 0.003, n = 20
  **Total Ly**1882±546 cells/µl, n = 26                          p = 0.596                         p\<0.001    p = 0.16   p = 0.02    r^2^ = 0.80, p\<0.001, n = 20

Values for independent and dependent variables represent mean ± standard deviation. HLE~CS~ ^+^ lymphocytes and CXCR4^+^ lymphocytes in the lymphocyte gate (Ly) were quantitated using flow cytometry. Active α~1~PI and CXCL12 were quantitated in serum as described.

Multilinear regression was performed to determine the relationship of the dependent variables to the independent variables using power of test α = 0.05. Dependent variables were considered to be significantly related to the independent variable if they contributed significantly to the multilinear regression (p\<0.05). In this population sample, variables were found to have constant variance and normality.

It was previously demonstrated that early in disease, 89% HIV-1 infected subjects have detectable antibody that is reactive with α~1~PI [@pone.0031383-Bristow6]. Two monoclonal antibodies (1C1 and 3F5) which bind a conformationally determined epitope near the C5 domain of gp120 were found to also bind human α~1~PI [@pone.0031383-Moore1]. To examine the possibility that antibodies reactive with α~1~PI might participate in the depletion of active α~1~PI, IgG-α~1~PI immune complexes were measured in all samples with sufficient residual volume. Of 22 HIV-1 infected and 21 HIV-1 uninfected individuals tested, 8 were found to be positive for detectable IgG-α~1~PI immune complexes, and all 8 were HIV-1 infected subjects. Significantly, IgG-α~1~PI immune complexes were correlated with CD4^+^ lymphocyte numbers (r^2^ = 0.822, p\>0.05, n = 8) and with serum inactive α~1~PI concentration (r^2^ = 0.988, p\>0.05, n = 8) ([**Fig. 1B**](#pone-0031383-g001){ref-type="fig"}).

Anti-gp120 inactivates human, but not chimpanzee α~1~PI {#s2c}
-------------------------------------------------------

It was hypothesized that anti-gp120 mediated depletion of active α~1~PI might be pathognomonic for HIV-1-induced AIDS. If true, this would suggest that chimpanzee α~1~PI differs from human α~1~PI since HIV-1 infected chimpanzees survive infection and regain normal numbers of CD4^+^ lymphocytes [@pone.0031383-Rutjens1]. Sequence comparison revealed that other than the known polymorphisms, human α~1~PI differs from chimpanzee α~1~PI by a single amino acid (aa 385) caused by a single nucleotide change (NCBI accession numbers BT019455 and XP_522938), and this variant amino acid lies in the α~1~PI region homologous to gp120. To determine whether this sequence difference influences the binding of anti-gp120 to α~1~PI, sera were compared from 18 HIV-1 uninfected humans and 20 HIV-1 uninfected chimpanzees.

In contrast to chimpanzee α~1~PI, binding of both 1C1 (data not shown) and 3F5 to human α~1~PI was elevated 8- to 14-fold above background in 6 repeat measurements (p\<0.001) ([**Fig. 2A**](#pone-0031383-g002){ref-type="fig"}). Negative control monoclonal antibody α70 which reacts with the V3-loop of gp120 failed to bind human α~1~PI consistent with previous findings [@pone.0031383-Bristow6], and there was no difference between binding of α70 to human or chimpanzee sera (p = 0.6). The markedly greater affinity for 3F5 exhibited by serum α~1~PI in two human subjects suggests that the epitope of α~1~PI recognized by 3F5 may be phenotypically determined. Even when these two subjects were omitted from the comparison, the statistical difference between binding of 3F5 to human versus chimpanzee α~1~PI was maintained (p\<0.001).

![Binding of anti-gp120 to human, but not chimpanzee α~1~PI.\
(**A**) Monoclonal antibody 3F5 (5 µg/ml) binding to α~1~PI in sera from 18 HIV-1 uninfected humans and 20 HIV-1 uninfected chimpanzees was measured using ELISA. Antibody bound (A~490\ nm~) was normalized for the active α~1~PI concentration in each specimen and is represented as A~490~nm/\[α~1~PI (µM)\]. Representative data from 6 measurements are depicted. Bars represent median values. Median 3F5 bound to human α~1~PI was 0.12 and to chimpanzee α~1~PI was 0.02. Negative control monoclonal antibody α70 (10 µg/ml) yielded A~490~nm = 0.02 when incubated with α~1~PI at concentrations varying between 3 µM and 540 µM. There was no difference in binding of α70 to human or chimpanzee sera (p\>0.6). (**B**) IgG-α~1~PI immune complexes (A~490\ nm~) were measured in sera from HIV-1 uninfected humans (n = 9), HIV-1 infected humans (n = 35), HIV-1 uninfected chimpanzees (n = 20), HIV-1 challenged chimpanzees (n = 2), rhesus monkeys pre-immunization and 2 time points post immunization (n = 12), and rhesus monkeys pre- and post-infection (n = 3). There was no significant difference in rhesus monkeys pre- and post-immunization, pre-and post-infection. Representative data of triplicate measurements are depicted. (**C**) Active α~1~PI was measured in HIV-1 uninfected humans (26 µM, n = 20), HIV-1 infected humans (18 µM, n = 35), HIV-1 uninfected chimpanzees (35 µM, n = 20), HIV-1 challenged chimpanzees (39 µM, n = 2), rhesus monkeys pre-immunization and 2 time points post immunization (36 µM, n = 12), and rhesus monkeys pre- and post-infection (43 µM, n = 3). There was no significant difference in rhesus monkeys pre- and post-immunization, pre-and post-infection. Bars represent median values. (**D**) Inactive α~1~PI was measured in HIV-1 uninfected (4 µM, n = 20) and HIV-1 infected humans (19 µM, n = 35). Bars represent median values. (**E**) Active α~1~PI levels in sera from 5 HIV-1 infected subjects after incubation with either medium (control) or with monoclonal antibody 3F5.](pone.0031383.g002){#pone-0031383-g002}

None of the sera from 20 HIV-1 uninfected chimpanzees, nor sera collected from 2 chimpanzees post-HIV-1 inoculation, had evidence of detectable IgG-α~1~PI immune complexes ([**Fig. 2B**](#pone-0031383-g002){ref-type="fig"}). The HIV-1 inoculated chimpanzees were confirmed to be HIV-1 infected, but to have normal numbers of CD4^+^ lymphocytes (personal communication, Dr. P.N. Fultz) [@pone.0031383-Girard1]. In addition, despite the presence of anti-gp120, there was no evidence of IgG-α~1~PI immune complexes in 12 rhesus macaques (median active α~1~PI = 36 µM) following immunization with simian/human immunodeficiency virus (SHIV 89.6) gp120 or gp140, or in 3 macaques infected with SHIV (median difference between pre- and post-immunization, A~490~nm = 0.08). Extensive *in vitro* ELISA and Western Blot analyses failed to demonstrate bi-molecular complexes between gp120 and α~1~PI which rules out the possibility that anti-gp120 association with α~1~PI was mediated by gp120. Further, the absence of detectable IgG-α~1~PI immune complexes in sera from HIV-1 infected chimpanzees suggests that gp120 and α~1~PI are not associated by aggregation in sera.

Consistent with previous evidence, the serum concentration of active α~1~PI in HIV-1 subjects (median 18 µM) was significantly below normal (median 26 µM, p\<0.001) ([**Fig. 2C**](#pone-0031383-g002){ref-type="fig"}) and inactive α~1~PI (median 19 µM), was significantly above normal (median 4 µM, p\<0.001) ([**Fig. 2D**](#pone-0031383-g002){ref-type="fig"}) [@pone.0031383-Bristow6]. In contrast to humans, active α~1~PI concentration in sera collected from the 2 chimpanzees post-HIV-1 inoculation (median 39 µM) were not different from normal human or chimpanzee sera (median 35 µM, p = 0.810) ([**Fig. 2E**](#pone-0031383-g002){ref-type="fig"}).

To determine whether α~1~PI becomes inactivated after complexing with the 3F5 anti-gp120 monoclonal antibody, 3F5 was incubated with sera samples from five healthy HIV-1 uninfected subjects. In comparison to control untreated sera, α~1~PI activity was significantly diminished to the same degree in all 3F5-treated sera (mean difference = 5.8±0.5 µM, p\<0.001) ([**Fig. 2E**](#pone-0031383-g002){ref-type="fig"}).

To determine whether 3F5 anti-gp120 is the same antibody that produces IgG-α~1~PI immune complexes in HIV-1 infected subjects, α~1~PI activity was quantitated in 22 sera in the presence or absence of added HIV-1 virions in a blinded manner. Sera from 13 HIV-1 infected subjects with undetectable HIV RNA and \>220 CD4 cells/µl, 5 of whom had detectable IgG-α~1~PI immune complexes, and 9 HIV-1 uninfected subjects were incubated with an inactivated simian immunodeficiency virus (SIV) chimera which expresses the HIV envelope (AT-2 SHIV) [@pone.0031383-Arthur1], [@pone.0031383-Rossio1]. The α~1~PI activity increased in 5 of 22 sera incubated with AT-2 SHIV, and these 5 sera were the same 5 sera from HIV-1 infected subjects that were found to have detectable IgG-α~1~PI immune complexes suggesting the α~1~PI-inactivating factor adsorbed by the virions might have been anti-gp120 ([**Table 3**](#pone-0031383-t003){ref-type="table"}). In contrast, active α~1~PI was unchanged in all 9 HIV-1 uninfected sera and in all 8 of the sera from HIV-1 infected subjects lacking detectable IgG-α~1~PI immune complexes. HIV-1 infected subjects with IgG-α~1~PI immune complexes were found to have significantly lower CD4 counts (median = 210) than subjects without α~1~PI-IgG immune complexes (median = 327, p = 0.045).

10.1371/journal.pone.0031383.t003

###### HIV-1 patient serum antibodies that bind the 3F5-recognized gp120 epitope are the same antibodies that bind and inactivate α~1~PI.

![](pone.0031383.t003){#pone-0031383-t003-3}

  Subject    IgG-α~1~PI (A~490\ nm~)[a](#nt105){ref-type="table-fn"}   Active α~1~PI+buffer   Active α~1~PI+SHIV   Active α~1~PI+3F5-complexed SHIV
  --------- --------------------------------------------------------- ---------------------- -------------------- ----------------------------------
  1                                  0.9955                                   25 µM                 30 µM                       24 µM
  2                                  1.0520                                   11 µM                 19 µM                       10 µM
  3                                  1.1305                                   15 µM                 30 µM                       13 µM
  4                                  1.5515                                    9 µM                 17 µM                        9 µM
  5                                  2.6410                                    5 µM                  8 µM                        5 µM

Sera were selected from HIV-1 infected subjects with undetectable HIV RNA (n = 13) or from HIV-1 uninfected subjects (n = 9). Of the 22 sera tested, only 5 exhibited increased α~1~PI activity in the presence of SHIV, and these 5 were the only specimens that were also positive for IgG-α~1~PI immune complexes (A~490~nm\>0.5). Immune complexes were undetectable in the other 17 sera and none of those sera exhibited a difference in α~1~PI activity in the presence of SHIV (Mean difference = 0.7 µM±1 µM).

To demonstrate the specificity of the inactivating factor adsorbed by AT-2 SHIV, virions were pre-complexed with 3F5 monoclonal anti-gp120 prior to incubation with sera. By ELISA, it was determined that incubating AT-2 SHIV (30 µg p24) with 20 ng 3F5 in 100 µl for 45 min at 23°C results in a binding ratio of 50 ng 3F5/µg p24. After pre-complexing with 3F5, AT-2 SHIV virions were unable to remove the α~1~PI-inactivating factor and had no effect on α~1~PI activity ([**Table 3**](#pone-0031383-t003){ref-type="table"}). These results demonstrate that 3F5 anti-gp120 in patient sera is the principal factor responsible for inactivating α~1~PI. Further, these results indicate that, as would be anticipated, anti-gp120 in patient sera has greater affinity for gp120 than for α~1~PI.

Discussion {#s3}
==========

Herein is shown that active α~1~PI counterbalances HLE~CS~ in regulating CD4^+^ lymphocyte blood levels in HIV-1 infected and uninfected subjects. In contrast to HIV-1 uninfected subjects, two important differences in the HIV-1 infected population with \>220 CD4 cells/µl are notable; 1) the dependence of absolute lymphocyte numbers on CXCL12, and 2) the lack of dependence of CD4^+^ lymphocytes on the number of CXCR4^+^ lymphocytes. Since there are fewer CXCR4^+^ lymphocytes in HIV-1 infected subjects (73%) and even fewer CD4^+^ lymphocytes (49%), yet no difference in serum CXCL12 or HLE~CS~ ^+^ lymphocytes, this suggests a flaw in the interaction between CXCR4 and CXCL12, presumably in bone marrow, that results in production of fewer CXCR4^+^ lymphocytes despite the presence of sufficient CXCL12. Alternatively, although the magnitude of CXCL12 in blood is small, CXCL12 might systemically influence the number of CXCR4^+^ lymphocytes by inducing their egress from blood into tissue. The increased CXCL12, HLE~CS~ ^+^ lymphocytes, and CD4^+^ lymphocytes in the presence of active liver disease in 11 HIV-1 infected patients suggests a potential regulatory axis between the liver and hematopoietic tissue that may include additional unknown factors.

In the HIV-1 uninfected population, CD4^+^ lymphocyte numbers were correlated with three factors including serum active α~1~PI, HLE~CS~ ^+^ and CXCR4^+^ lymphocyte numbers. Since HLE~CS~ and CXCR4 are known to participate in regulating hematopoiesis, this suggests α~1~PI, HLE~CS~ and CXCR4 regulate the number of CD4^+^ lymphocytes. Because CD4^+^ lymphocyte numbers were correlated with serum active α~1~PI concentration with such a high degree of significance in HIV-1 infected subjects with \>220 CD4 cells/µl (r^2^ = 0.927, p\<0.0001), it can be concluded that there is a direct regulatory link between active α~1~PI and CD4^+^ lymphocyte numbers although this doesn\'t show causality. Because we have previously demonstrated that α~1~PI augmentation therapy produced an increase in the number of circulating CD4^+^ lymphocytes in HIV-1 infected and uninfected subjects, it can be concluded that α~1~PI regulates the number of CD4^+^ lymphocytes in blood [@pone.0031383-Bristow1]. Since active α~1~PI regulates CD4^+^ lymphocyte numbers, yet HLE~CS~ ^+^ and CXCR4^+^ lymphocyte numbers appear not to contribute to regulation in the HIV-1 infected subjects, it can be concluded that active α~1~PI is the rate limiting factor for regulating CD4^+^ lymphocyte numbers in HIV-1 infected subjects. Whether the influence of α~1~PI on hematopoiesis occurs in bone marrow, the thymus, or elsewhere is currently being investigated.

Three distinct activities of α~1~PI are performed by moieties within the carboxyl terminal of the protein: (1) inhibition of soluble HLE~G~ mediated by active site residue Met^358^; disruption of this activity results in emphysema and respiratory-related infections; (2) induction of receptor polarization and cell migration mediated by α~1~PI residues ^370^ FVFLM^374^ [@pone.0031383-Bristow3]; evidence suggests that this domain stimulates cell motility and is responsible for the binding of HLE~CS~- α~1~PI complexes to members of the LDL receptor family [@pone.0031383-Joslin1], [@pone.0031383-Janciauskiene1]; and (3) binding of α~1~PI to antibodies reactive with HIV-1 gp120 [@pone.0031383-Bristow6]; functional α~1~PI deficiency in HIV-1 disease was previously shown to be caused primarily by IgG-α~1~PI immune complex formation, not by impaired synthesis, proteolysis, or oxidation [@pone.0031383-Bristow6]. IgG-α~1~PI immune complexes were not detected in all HIV-1 infected subjects, and this may be due to the presence of immunoglobulin subclasses other than IgG, the inability to capture α~1~PI bound in immune complexes with high IgG content, or their absence in some individuals [@pone.0031383-Virella1].

The gp120 epitope recognized by the 1C1 and 3F5 antibodies is considered to be conformation-dependent [@pone.0031383-Moore2]. The gp120 peptide immunogen used to raise 1C1 and 3F5 (^471^GGGDMRDNWRSELYKYKVVK^490^) [@pone.0031383-Ratner1] contains both an α-helix (aa 476--484) and linear strand (aa 485--490) ([**Fig. 3A,B**](#pone-0031383-g003){ref-type="fig"}), but other epitope determinants of the antibodies are not known. Human α~1~PI, which also binds 1C1 and 3F5, contains ([**Fig. 3C,D**](#pone-0031383-g003){ref-type="fig"}), the gp120-homologous sequence (^369^PFVFLMIDQNTKSPLFMGKVV^389^) that folds to form a two-stranded antiparallel β-sheet lying at the base of a cleft (4 Å deep by 20 Å long by 5 Å wide) topped by two α-helices (aa 27--44 and 259--277) in a smaller, but similar configuration as the antigen-binding cleft of MHC (10 Å deep by 25 Å long by 10 Å wide) [@pone.0031383-Bjorkman1]. At the end of the first of these α-helices is the N-linked mannose-containing oligosaccharide that confers structural polymorphism to α~1~PI (N-linkage at Asn-46) [@pone.0031383-Jeppsson1]. In the center of the β-sheet that lies in the cleft is Met-385 which distinguishes human from chimpanzee α~1~PI (equivalent residue = Val-385). Although the function of this cleft is not known, a sequence in the center of the β-sheet formation (^370^FVFLM^374^) is homologous to the fusion domain of HIV-1 gp41 [@pone.0031383-Bristow5], and this sequence has been implicated in binding to members of the LDL receptor family and in stimulating cell migration [@pone.0031383-Strickland2] [@pone.0031383-Joslin1].

![Corresponding conformation at the 3F5-recognized epitope in α~1~PI and CD4-complexed HIV-1 gp120.\
HIV-1 gp120 is depicted from two perspectives (**A,B**) with green representing two α-helices (aa 100--115 and 476--484). The gp120 peptide immunogen used to raise 1C1 and 3F5 (aa 471--490) is located at the C-terminus of gp120, and the linear segment ^486^YKVV^489^ is depicted in red along with Met95 and the oligosaccharide-linked segment ^234^NGT^236^, all of which are within 8 Å of the conformational epitope. The gp120-homologous domain in α~1~PI is also located at the C-terminus of the protein, and is depicted from two perspectives (**C,D**) with violet representing the antiparallel β-sheet strand at the base of the cleft (aa 369--389), and green representing the α-helices that form the mouth of the cleft (aa 27--44 and 259--277). Met-385, which distinguishes human from chimpanzee α~1~PI, is depicted in red along with the segment ^386^GKVV^389^, the oligosaccharide, and oligosaccharide-linked segment ^46^NST^48^. The HLE~G~-reactive site Met-358, is depicted in yellow for orientation. Structures for human α~1~PI (1HP7) and CD4-complexed HIV-1 gp120 (1RZJ) from the NCBI Molecular Modeling Database (MMDB) were analyzed using Cn3D software. Small carbohydrate structures, depicted in multiple colors, were associated with 1RZJ in MMDB, and the three associated with 1HP7 were added using Adobe Photoshop.](pone.0031383.g003){#pone-0031383-g003}

Within the α~1~PI protein, the sequence ^386^GKVV^389^ lies within 5 Å of Met-385 and Asn-46 with its N-linked oligosaccharide in a space occupying 5 Å by 5 Å by 5 Å. In the same relative orientation as in α~1~PI, the gp120 sequence ^486^YKVV^489^ lies within 5 Å of Met-95 and 8 Å of Asn-234 with its N-linked mannose-containing oligosaccharide [@pone.0031383-Leonard1] in a space of dimensions 5 Å by 5 Å by 8 Å. Significantly, the gp120 Asn-234 is invariant [@pone.0031383-Wei1]. The N-linked oligosaccharide of α~1~PI Asn-46 confers polymorphism, and our observation that 3F5 binding to α~1~PI in 2 control sera is much greater than in the other 16 control sera ([Fig. 3a](#pone-0031383-g003){ref-type="fig"}) suggests this oligosaccharide may reside within the 3F5 epitope. Thus, these spatial analyses suggest that the 3F5 conformational epitope occupies a space approximately 5 Å by 5 Å by 8 Å which includes KVV, M, N, and the N-linked oligosaccharide. The dimensions of this proposed conformational epitope are consistent with previously characterized 8 Å by 7 Å antigens that contain oligosaccharide determinants [@pone.0031383-Cygler1].

Comparison of the amino acid sequences of human α~1~PI, HIV-1, HIV-2, SIV (including SIV~CPZ~), HTLV-1, and HTLV-2 reveals that all share homology with the hydrophobic core of the fusion domain of HIV-1 gp41 (LFLGFL), but only HIV-1 gp120 shares homology with the C-terminal domain of α~1~PI [@pone.0031383-Bristow6]. This observation is consistent with the species-specific differences in disease caused by the corresponding immunodeficiency viral infections. For example, neither SIV nor HTLV produce AIDS in their natural hosts [@pone.0031383-Freissmuth1]. SIV causes CD4 depletion in some simian species, but the progression to AIDS is disproportionately faster than in HIV-1 infection of humans. HIV-2 infection may induce AIDS, however, the frequency of AIDS incident to HIV-2 infection is 20-fold lower than for HIV-1, suggesting a variant mechanism of disease progression [@pone.0031383-Marlink1]. That antibodies reactive with α~1~PI are produced in response to a homologous sequence unique to HIV-1 suggests this immune reaction distinguishes HIV-1 infection from other retroviral infections. Importantly, a single amino acid differentiates chimpanzee α~1~PI from human α~1~PI, and this difference is in the HIV-1 gp120 homologous domain, perhaps explaining the lack of progression to AIDS in HIV-1 infected chimpanzees [@pone.0031383-Rutjens1].

Molecular mimicry by viruses accommodates non-disruptive incorporation into its natural host thereby facilitating reproduction and avoiding immune clearance. Cross-species virus infection produces a situation in which molecular mimicry is less efficient thereby leading to an inflammatory response and immune recognition. Such situations can secondarily produce autoimmunity. Considering that the proteinases and proteinase inhibitors that maintain homeostasis are species-specific, the variable disease sequelae caused by SIV infection in variant monkey species could be due to the interaction of SIV or anti-SIV with a variety of homologous proteinases and proteinase inhibitors involved in homeostasis, for example, coagulation and complement proteins. Similarly, the variation in onset and course of HIV-1 and HIV-2 disease in man could be caused by differences in the interaction of HIV-1, HIV-2, anti-HIV-1, or anti-HIV-2 with various blood components involved in homeostasis. The binding of HIV-1-specific antibodies to human proteins is well-established, for example, Mac-1 [@pone.0031383-Rubinstein1], cardiolipin [@pone.0031383-Haynes1], inter-α-trypsin inhibitor [@pone.0031383-Koito1], and MHC Class II [@pone.0031383-Golding1]. In one study, 49 of 150 HIV-1 infected subjects were found to have autoantibodies reactive with conjugated fatty acids [@pone.0031383-Amara1] Evidence presented here and elsewhere suggests that inactivation of α~1~PI by anti-gp120 is the fundamental reason CD4^+^ lymphocytes fail to be replenished and that α~1~PI augmentation therapy can overcome this autoimmune phenomenon and re-establish normal levels of CD4^+^ lymphocytes [@pone.0031383-Bristow1].

The ability of HIV-1 virions to liberate α~1~PI from anti-gp120 antibodies is not surprising since HIV-1, not α~1~PI, is the immunogen. The competitive advantage of HIV-1 for binding to anti-gp120 provides a unique method for therapeutically liberating α~1~PI by blocking autoimmune antibodies. In this manner, humans might co-exist with HIV-1, as chimpanzees do, without developing AIDS. Theoretically, modification of candidate HIV-1 vaccines so that antibodies that react with human proteins are avoided altogether provides a means to develop a vaccine that protects against AIDS as opposed to the current approach to develop a vaccine that protects against HIV-1 infection.

Materials and Methods {#s4}
=====================

Ethics Statement {#s4a}
----------------

Collection of blood from research subjects was approved by the institutional review board of Cabrini Medical Center. Written informed consent was obtained from all subjects prior to participation in these studies. Residual sera from chimpanzees were purchased or approved for use by the LEMSIP IACUC.

Human subjects {#s4b}
--------------

After obtaining informed consent, blood was collected from 30 HIV-1 seronegative, healthy adults, 14 males and 16 females, and from 39 HIV-1 seropositive adults attending clinic, 37 males and 2 females. Two of the HIV-1 uninfected individuals were healthy adults with the inherited version of α~1~PI deficiency (PI~ZZ~) and exhibited 41% and 42% CD4^+^ lymphocytes (reference range = 34%--58%). HIV-1 infected individuals with malignancies (n = 4) were omitted from analyses of CD4^+^ lymphocyte levels and are being evaluated separately. Of the remaining 35 HIV-1 infected individuals included in the study, 11 had evidence of active liver disease.

Rhesus serum (Macaca mulatta) {#s4c}
-----------------------------

Adult monkeys were immunized with SHIV or were infected with SHIV 89.6 as described in a previous report [@pone.0031383-Letvin1]. Residual sera from 12 immunized and 3 infected monkeys were obtained from Dr. D.C. Montefiori with approval from the Duke University Medical Center IACUC.

Chimpanzee serum (Pan troglodytes) {#s4d}
----------------------------------

Residual sera from 20 uninfected HIV-1 adult chimpanzees, 10 males and 10 females, were purchased from YERKES Regional Primate Center of Emory University. Residual sera from 2 chimpanzees collected pre- and 42 months post-HIV-1 challenge were obtained from LEMSIP of NYU Medical Center after obtaining approval from the LEMSIP IACUC [@pone.0031383-Girard1], [@pone.0031383-Rodman1]. One chimpanzee was inoculated IV with cell-free HIV-DH12 [@pone.0031383-Girard2]. The other chimpanzee was inoculated twice via the cervical os with HIV-infected peripheral blood cells from a chimpanzee infected with HIV LAI/IIIB and once IV with cell-free HIV-LAI/IIIB [@pone.0031383-Girard1]. Both chimpanzees were previously confirmed to be infected and to have normal CD4^+^ lymphocyte levels [@pone.0031383-Girard1].

Flow cytometric analysis {#s4e}
------------------------

Surface staining for markers on cells was performed by incubating whole blood for 15 min at 23°C with anti-CD4-FITC, anti-CXCR4-PE, anti-CCR5-PE, isotype controls (BD Biosciences, San Diego, CA). Cells were subsequently stained to detect HLE~CS~ by incubating whole blood for an additional 15 min at 23°C with rabbit anti-HLE (Biodesign, Kennebunkport, ME) or negative control rabbit IgG (Chemicon, Temecula, CA) which had been conjugated to Alexa Fluor 647 (Molecular Probes, Eugene, OR). After lysing red blood cells and washing, stained cells were fixed. At least 10,000 cells from each sample were acquired using a FACSCalibur flow cytometer. Markers on cells in the lymphocyte gate were quantitated, and CD4^+^ cells in the lymphocyte gate were compared with measurements obtained from an outside contractor to validate gating. In all cases CD4^+^ lymphocyte numbers were within 95% agreement between the two laboratories. Cell staining was analyzed using CellQuest (BD Biosciences) or FlowJo software (Tree Star, Inc., Ashland, OR).

Quantitation of serum CXCL12, α~1~PI, α~2~M, and anti-α~1~PI {#s4f}
------------------------------------------------------------

Serum CXCL12 was measured in duplicate using an ELISA kit according to the manufacturer (R&D Systems, Minneapolis, MN). Total serum α~1~PI protein was determined in 8 serial serum dilutions by ELISA using previously described methods with the modification that serum dilution buffers contained 10 mM EDTA [@pone.0031383-Bristow7]. Active and inactive fractions of α~1~PI in once-thawed sera were detected using inhibition of porcine pancreatic elastase (PPE, Sigma, St. Louis, MO) as previously described [@pone.0031383-Bristow7] with the modification that end-point, rather than kinetic, analysis was measured [@pone.0031383-Bristow7]. IgG-α~1~PI immune complexes were measured in triplicate in phosphate buffered saline pH 7.2 by incubating sera in wells of a microtiter plate pre-coated with chicken anti-human α~1~PI IgG (OEM Concepts, Toms River, NJ) as previously described [@pone.0031383-Bristow6], and captured α~1~PI-complexed IgG was detected using peroxidase-conjugated rabbit anti-human IgG (Sigma), a reagent that was confirmed to react with chimpanzee and rhesus macaque IgG. Serum from HIV-1 uninfected subjects that had been collected into tubes containing clot activating additive were excluded from immune complex analysis because of buffer incompatibility.

Binding of anti-gp120 antibody to α~1~PI {#s4g}
----------------------------------------

Human or chimpanzee sera from HIV-1 uninfected subjects were diluted 1∶10 in 200 µl phosphate buffered saline containing, 5% fish gelatin and 10 mM EDTA to which was added 10 µl containing 1 µg murine monoclonal antibodies 1C1 (Repligen, Inc., Cambridge, MA) or 3F5 (hybridoma culture supernatant, 0085-P3F5-D5-F8, a generous gift from Dr. Larry Arthur, NCI-Frederick). Monoclonal 1C1 and 3F5 were raised against a peptide immunogen from the HIV-1 gp120 C5 domain (aa 471--490, GGGDMRDNWRSELYKYKVVK) [@pone.0031383-Moore2] and bind a conformational epitope [@pone.0031383-Moore1]. Alternatively, sera were incubated with 10 µl containing 2 µg negative control antibody Clone α70 (ICN Biochemicals, Aurora, OH) reactive with the V3 loop of HIV-1 gp120. Immune complexes that were formed by adding anti-gp120 monoclonal antibodies to human or chimpanzee sera were captured by incubating sera in wells of a microtiter plate pre-coated with chicken anti-human α~1~PI IgG (OEM Concepts). Binding was detected using horse radish peroxidase-conjugated rabbit anti-mouse IgG (Sigma) followed by substrate, orthophenylene diamine HCl.

Inactivated virus adsorption of antibodies from α~1~PI {#s4h}
------------------------------------------------------

The AT-2-inactivated SHIV preparation used in this study was generously provided by Jeff Lifson, Julian Bess, and Larry Arthur of the AIDS Vaccine Program (SAIC-Frederick, National Cancer Institute at Frederick, Frederick, MD, USA). Chemically inactivated non-infectious virus with conformationally and functionally intact envelope glycoproteins was produced by treatment with AT-2 as described [@pone.0031383-Arthur1], [@pone.0031383-Rossio1]. The SHIV89.6 virus was produced from the CEM X 174 (T1) cell line [@pone.0031383-Arthur1]. Virus content of purified concentrated preparations was determined with an antigen capture immunoassay for capsid protein (AIDS Vaccine Program). Virus stocks were diluted in 1% BSA (Intergen, New York, NY, USA) in Dulbecco\'s PBS and stored as aliquots (3 µg capsid protein/ml) at −80°C until use.

To determine the adsorption of anti-gp120 antibodies from α~1~PI, AT-2 SHIV (3 µg/ml) or dilution buffer (Dulbecco\'s PBS +1% BSA) were added to an equal volume of serum and incubated for 30 min at 23°C prior to measuring α~1~PI activity. To demonstrate the specificity of antibody adsorption, AT-2 SHIV virions (5.5 µg/120 µl) were pre-incubated with 3F5 monoclonal anti-gp120 (10.5 µg/500 µl) or dilution buffer (500 µl) for 60 min at 23°C prior to with serum. Unbound 3F5 was removed by centrifugation of AT-2 SHIV virions at 14,000 g for two hrs, and virions were resuspended in 120 µl Tris-buffered saline, pH7.8, containing 10 mM EDTA.

Statistical Analysis {#s4i}
--------------------

Least squares linear and multiple linear regression were performed using SigmaPlot. Unless other stated, Measurements are presented as mean ± standard deviation for absolute lymphocyte counts, CD4^+^, CXCR4^+^, CCR5^+^, and HLE~CS~ ^+^ lymphocytes, as well as serum concentrations of CXCL12, total α~1~PI, active α~1~PI, inactive α~1~PI, IgG-α~1~PI immune complexes, and 3F5 anti-gp120 binding to human and chimpanzee α~1~PI. Absolute lymphocyte counts, CXCR4^+^, and CCR5^+^ lymphocytes were normally distributed, and means were compared. HLE~CS~ ^+^ lymphocytes, and serum concentrations of CXCL12, active α~1~PI, inactive α~1~PI, IgG-α~1~PI immune complexes, and 3F5 anti-gp120 binding to human and chimpanzee α~1~PI were not normally distributed, and medians were compared. CD4^+^ lymphocytes were normally distributed in the HIV-1 uninfected subjects, but not normally distributed in the HIV-1 infected subjects, and medians were compared. Means were compared using Student\'s t-test, and medians were compared using the Mann-Whitney Rank Sum Test.
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